Deerfield Management is a New York-based healthcare-dedicated investment firm managing multi-billion dollar assets across public equities, venture, and philanthropy. It operates across the full healthcare spectrum including biopharma, medtech, and digital health, typically at later stages. Deerfield has participated in neurotech financing rounds, including leading the Series C-1/C-2 round for Presidio Medical in 2023 (a neuromodulation company developing Ultra-Low Frequency Spinal Cord Stimulation for chronic pain, $72M round). Deerfield is most relevant for neurotech companies at later stages with clinical data and a clear path to commercial deployment.